Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
4
Neutral
7
Bullish
3
Bearish
5
Neutral
7
Bullish
34
Bearish
1
Neutral
0
Bullish
31
Discovery themes featuring this stock
Aurobindo Pharma Limited is a global pharmaceutical company that develops, manufactures and markets active pharmaceutical ingredients (APIs), generic formulations, injectables and a growing biosimilars portfolio across regulated and growth markets, operating multiple manufacturing sites and R&D centres to serve over 150 countries with a broad ANDA/DMF filing base and expanding biologics capabilities.
Q3FY26 consolidated revenue reached Rs. 8,646 crore, up 8.4% YoY, with EBITDA of Rs. 1,773 crore (20.5% margin) and net profit of Rs. 910 crore; management highlighted stable US base business, strong European growth (+27% YoY) and R&D spend of Rs. 409 crore (4.7% of sales) focused on biosimilars and specialty products development.
Biosimilars (CuraTeQ) are a strategic growth pillar: multiple 2025 approvals in EEA/UK/Canada, filings planned in EMA and Health Canada, two Phase‑3 programs ongoing and planned US/EU BLA/MAA engagement for denosumab and omalizumab in 2026, positioning Aurobindo for a biotech revenue inflection toward 2028–2029.
Operationally, Aurobindo reported meaningful capex and cash generation: net capex of US$79mn in the quarter, free cash flow generation of US$118mn and a strong net cash position (~US$251mn after appropriations), enabling both organic capacity build and selective M&A such as the Lannett transaction under regulatory review.
Key near‑term drivers include: commercialization momentum in Europe, ramp of Pen‑G/6‑APA capacity with Govt MIP support, continued ANDA approvals and product launches in the US, and biosimilars commercialization and filings that together create multi‑year earnings visibility across segments.
Pharmaceuticals & Biotechnology
Pharmaceuticals
77,592 Cr
Low Risk
22.3
30.9
1.1
2.2
1,359.00
994.35
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stockUpcoming Result Date: Apr 05, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Aurobindo Pharma Ltd (AUROPHARMA) is currently trading at 1,335.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Aurobindo Pharma Limited is a global pharmaceutical company that develops, manufactures and markets active pharmaceutical ingredients (APIs), generic formulations, injectables and a growing biosimilars portfolio across regulated and growth markets, operating multiple manufacturing sites and R&D centres to serve over 150 countries with a broad ANDA/DMF filing base and expanding biologics capabilities. Q3FY26 consolidated revenue reached Rs. 8,646 crore, up 8.4% YoY, with EBITDA of Rs. 1,773 crore (20.5% margin) and net profit of Rs. 910 crore; management highlighted stable US base business, strong European growth (+27% YoY) and R&D spend of Rs. 409 crore (4.7% of sales) focused on biosimilars and specialty products development. Biosimilars (CuraTeQ) are a strategic growth pillar: multiple 2025 approvals in EEA/UK/Canada, filings planned in EMA and Health Canada, two Phase‑3 programs ongoing and planned US/EU BLA/MAA engagement for denosumab and omalizumab in 2026, positioning Aurobindo for a biotech revenue inflection toward 2028–2029. Operationally, Aurobindo reported meaningful capex and cash generation: net capex of US$79mn in the quarter, free cash flow generation of US$118mn and a strong net cash position (~US$251mn after appropriations), enabling both organic capacity build and selective M&A such as the Lannett transaction under regulatory review. Key near‑term drivers include: commercialization momentum in Europe, ramp of Pen‑G/6‑APA capacity with Govt MIP support, continued ANDA approvals and product launches in the US, and biosimilars commercialization and filings that together create multi‑year earnings visibility across segments.
Over the past 52 weeks, Aurobindo Pharma Ltd has traded between a low of ₹994.35 and a high of ₹1,359.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Aurobindo Pharma Ltd has a market capitalization of approximately 77,592.19. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Aurobindo Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 22.25 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 77,592.19 Cr, Aurobindo Pharma Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Aurobindo Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Aurobindo Pharma Ltd is 22.25. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
An 'Official Action Indicated' (OAI) classification is issued by the US FDA when an inspection reveals significant objectionable conditions or practices that warrant regulatory or administrative action. It is the most serious classification and can lead to delays in product approvals.
An OAI status means the US FDA found objectionable conditions during an inspection and regulatory or administrative actions are recommended. It is a more serious classification than 'Voluntary Action Indicated' and can lead to warning letters or import alerts.
The USFDA issued nine observations citing severe lapses in sanitation, data integrity, and procedural controls. Key issues included extreme cross-contamination, presence of E. Coli, falsification of data by a microbiologist, and inadequate computer system controls.
Aurobindo Pharma reported an 8.4% year-on-year revenue growth to ₹8,646 crore and a 7.5% increase in net profit to ₹909.8 crore. EBITDA margin expanded to 20.5%.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1193.40 | 96,401 Cr | 21.21 | 2.93 | 1.34 | 16.53 | 21.05 | 11.32 | ||
864.25 | 86,964 Cr | 17.61 | 3.44 | 1.27 | 19.44 | 19.08 | 10.52 | ||
1990.00 | 82,460 Cr | 46.23 | 5.39 | 0.00 | 11.45 | 12.34 | 6.26 | ||
1335.95 | 77,592 Cr | 22.25 | 2.21 | 0.00 | 9.77 | 12.69 | 6.63 | ||
5271.35 | 62,857 Cr | 26.58 | 4.71 | 0.86 | 17.69 | 18.13 | 11.95 | ||
2090.85 | 59,101 Cr | 55.43 | 6.17 | 0.12 | 26.24 | 30.84 | 5.60 | ||
352.55 | 57,145 Cr | 84.72 | 1.51 | 0.11 | 1.81 | 4.20 | 1.00 | ||
| Median: 7 Co. | — | 1335.95 | 77,592 Cr | 26.58 | 3.44 | 0.12 | 16.53 | 18.13 | 6.63 |
Buyback Proposal
Aurobindo Pharma notified exchanges that its Board will meet on April 6, 2026 to consider a proposal for buyback of fully paid equity shares; trading window remains closed until 48 hours after FY2026 audited results.
Buyback Proposal
Aurobindo Pharma informed exchanges that its Board will meet on April 6, 2026 to consider a proposal for buyback of fully paid-up equity shares; trading window closed from April 1 until 48 hours after audited FY2025‑26 results are declared.
